Category: Fresenius Medical Care
Dialysis services provider Fresenius gives its renal research arm a new look, renaming it "Frenova" and reasserting its focus on new product development.
Dialysis giant Fresenius (NYSE:FMS) re-introduced its renal research branch, renaming it "Frenova" and reiterating the group's commitment to developing novel therapies.
Here's a look at some of the top Wall Street stories for medical device companies this week.
Biomet is planning to put itself back on the public market after a 7-year run under private equity ownership, the orthopedics giant said today.
, Goldman Sachs
, Kohlberg Kravis Roberts & Co. L.P.
, Semler Scientific
, Terumo Corp.
, The Blackstone Group LP
, TPG Capital
, Analogic Corp.
, Fresenius Medical Care
, GE Healthcare
, Getinge AB
QMed releases a list of the 5 worst-performing medical device companies of early 2014, including Siemens, GE and Fresenius, among others.
MASSDEVICE ON CALL — Medtech giants have seen Wall Street bumps so far this year, but several of the company's in the industry's top 40 haven't been so fortunate.
Fresenius renews its pact for the purchase of NxStage Medical's System One hemodialysis device.
Fresenius (NYSE:FMS) and NxStage Medical (NSDQ:NXTM) said they extended a supply deal for NxStage's System One hemodialysis device until 2016.
A Federal Circuit court refuses to re-hear the case after a lower court throws out Baxter's $23.5 million win against Fresenius, which was charged with infringement of hemodialysis patents.
Legal troubles escalate for German healthcare giant Fresenius, which now faces a class action lawsuit over its dialysis drug GranuFlo.
Hundreds of lawsuits against Fresenius (NYSE:FMS) escalated into a class action filed in California state court with patients claiming that the German healthcare company intentionally hid serious health risks associated with its dialysis drug GranuFlo.
The FDA hands German healthcare group Fresenius a warning letter over violations cited after an April inspection of a Puerto Rico facility.
The FDA took issue with certain manufacturing processes at a Fresenius (NYSE:FMS) plant in Puerto Rico, handing the German medical healthcare company its 3rd warning letter this year.